JNJ 61393215Alternative Names: JNJ-61393215
Latest Information Update: 11 Jan 2017
At a glance
- Originator Janssen-Cilag
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 30 Dec 2016 Janssen Research & Development plans a phase I trial (In volunteers) in Netherlands (NCT03007693)
- 01 Nov 2016 Janssen-Cilag International completes enrolment in its phase I trial (In volunteers) in Netherlands (NCT02812251)
- 01 Jul 2016 Phase-I clinical trials in Undefined indication (In volunteers) in Netherlands (PO) (NCT02812251)